Ad
related to: curis inc stock price- thinkorswim®
Access The Award-Winning Platform
Built By Traders, For Traders.
- Start Trading Today
Open Your Brokerage Account With
Schwab For No Trade Minimums.
- thinkorswim®
Search results
Curis, Inc. (NASDAQ:CRIS) Shares Fly 75% But Investors Aren't Buying For Growth
Simply Wall St. via Yahoo Finance· 1 year agoCuris, Inc. (NASDAQ:CRIS) shareholders would be excited to see that the share price has had a great...
Curis, Inc. (NASDAQ:CRIS) Surges 54% Yet Its Low P/S Is No Reason For Excitement
Simply Wall St. via Yahoo Finance· 5 months agoCuris, Inc. (NASDAQ:CRIS) shareholders would be excited to see that the share price has had a great...
Investors in Curis (NASDAQ:CRIS) from five years ago are still down 87%, even after 15% gain this...
Simply Wall St. via Yahoo Finance· 2 years agoCuris, Inc. (NASDAQ:CRIS) shareholders should be happy to see the share price up 30% in the last...
What Kind Of Shareholders Hold The Majority In Curis, Inc.'s (NASDAQ:CRIS) Shares?
Simply Wall St. via Yahoo Finance· 2 years agoEvery investor in Curis, Inc. (NASDAQ:CRIS) should be aware of the most powerful shareholder groups....
Is Curis, Inc. (NASDAQ:CRIS) Trading At A 47% Discount?
Simply Wall St. via Yahoo Finance· 12 months agoKey Insights Using the 2 Stage Free Cash Flow to Equity, Curis fair value estimate is US$1.58...
Strength Seen in Curis (CRIS): Can Its 19.5% Jump Turn into More Strength?
Zacks via Yahoo Finance· 2 months agoCuris (CRIS) was a big mover last session on higher-than-average trading volume. The latest trend in...
Curis (CRIS) Reports Q3 Loss, Misses Revenue Estimates
Zacks via Yahoo Finance· 2 years agoCuris (CRIS) delivered earnings and revenue surprises of 17.65% and 6.77%, respectively, for the...
Curis (CRIS) Lymphoma Study's Clinical Hold Lifted, Shares Gain
Zacks via Yahoo Finance· 2 years agoThe FDA lifts partial clinical hold on Curis' (CRIS) phase I/II TakeAim lymphoma study investigating...
Curis Shares Gain On Encouraging Data Presentation From Blood Cancer Trials At ASCO Meeting
Benzinga via Yahoo Finance· 2 years agoCuris Inc (NASDAQ: CRIS) presented clinical data from the TakeAim Lymphoma and TakeAim Leukemia...
Curis Resumes Enrollment In Monotherapy TakeAim Leukemia Study, Combo Phase Still Under Partial Hold
Benzinga via Yahoo Finance· 2 years agoThe FDA has notified Curis Inc (NASDAQ: CRIS) to resume enrollment of additional patients in the...
